Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells.
Eur J Pharmacol · 2017
Last updated 2026-05-28In a lab study, the GLP-1 drug liraglutide reduced the growth of liver cancer cells (HepG2) without changing oxidative stress levels. The drug triggered two processes—autophagy (cell cleanup) and senescence (cell aging)—likely by increasing levels of a protein called TGF-β1.
AI summary of the abstract below.
| Journal | Eur J Pharmacol, 2017 |
|---|---|
| Citations | 35 |
| Relative citation ratio | 1.35 |
| NIH percentile | 61 |
| Molecules | liraglutide |
| Conditions studied | Mash |
Abstract
It has been reported that glucagon-like peptide-1 (GLP-1) agents have been associated with both the increased risk of cancer and inhibition of tumor growth and metastases. The aim of this study is to evaluate the effect of liraglutide on hepatocellular carcinoma cells - HepG2. Cytometry was used to evaluate mechanism related to decreased cell proliferation. Nuclear staining and morphometric analysis were also used to verify the process that was taking place after treatment with liraglutide, and in order to better understand the mechanism, TGF-β1 was performed. HepG2 cells decreased proliferation after liraglutide treatment without altering oxidative stress levels. Liraglutide was able to induce autophagy and senescence through the increase of TGF-β1 which possibly explains the growth decrease. We have demonstrated that liraglutide has an antiproliferative effect in HepG2 cells inducing autophagy and senescence by the increase of TGF-β1.
Verbatim abstract via PubMed 28501576 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.